Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines - PubMed (original) (raw)
Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines
A Puisieux et al. FASEB J. 1993 Nov.
Abstract
We analyzed the status of retinoblastoma and p53 genes in 10 human hepatoma cell lines. Polyclonal anti-peptide antibodies generated against peptides homologous to COOH-terminal and leucine-zipper domains of the retinoblastoma protein allowed us to identify two cell lines (Hep 3B and FOCUS) with abnormal expression. The same cell lines have both lacked p53 expression. In contrast to the retinoblastoma gene, the expression of the p53 gene was abnormal in six additional cell lines. Indeed, only the Hep G2 hepatoblastoma cell line (and its derivative Hep G2/2215) appeared to have normal p53 and retinoblastoma gene expression. Our studies indicate that p53 abnormalities are common but retinoblastoma gene aberrations are rare in human hepatoma cell lines.
Similar articles
- Alterations of the RB tumour suppressor gene in hepatocellular carcinoma and hepatoblastoma cell lines in association with abnormal p53 expression.
Farshid M, Hsia CC, Tabor E. Farshid M, et al. J Viral Hepat. 1994;1(1):45-53. doi: 10.1111/j.1365-2893.1994.tb00061.x. J Viral Hepat. 1994. PMID: 8790559 - Molecular analysis of the p53 alleles in primary hepatocellular carcinomas and cell lines.
Hosono S, Lee CS, Chou MJ, Yang CS, Shih CH. Hosono S, et al. Oncogene. 1991 Feb;6(2):237-43. Oncogene. 1991. PMID: 1847999 - [Co-inactivation of the p53 and RB genes in human hepato cellular carcinoma].
Murakami Y. Murakami Y. Nihon Rinsho. 1993 Feb;51(2):375-9. Nihon Rinsho. 1993. PMID: 8096551 Review. Japanese. - [Oncogenes and suppressor oncogenes in C-type hepatocellular carcinoma].
Tsukiyama-Kohara K. Tsukiyama-Kohara K. Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):619-23. Nihon Rinsho. 2004. PMID: 15359872 Review. Japanese. No abstract available.
Cited by
- RETRACTED: Insulin-like growth factor-binding protein-7 (IGFBP7): a promising gene therapeutic for hepatocellular carcinoma (HCC).
Chen D, Siddiq A, Emdad L, Rajasekaran D, Gredler R, Shen XN, Santhekadur PK, Srivastava J, Robertson CL, Dmitriev I, Kashentseva EA, Curiel DT, Fisher PB, Sarkar D. Chen D, et al. Mol Ther. 2013 Apr;21(4):758-66. doi: 10.1038/mt.2012.282. Epub 2013 Jan 15. Mol Ther. 2013. PMID: 23319057 Free PMC article. Retracted. - Apicidin-resistant HA22T hepatocellular carcinoma cells massively promote pro-survival capability via IGF-IR/PI3K/Akt signaling pathway activation.
Hsu HH, Cheng LH, Ho TJ, Kuo WW, Lin YM, Chen MC, Lee NH, Tsai FJ, Tsai KH, Huang CY. Hsu HH, et al. Tumour Biol. 2014 Jan;35(1):303-13. doi: 10.1007/s13277-013-1041-3. Epub 2013 Aug 30. Tumour Biol. 2014. PMID: 23990456 - Mutant p53 as an Antigen in Cancer Immunotherapy.
Sobhani N, D'Angelo A, Wang X, Young KH, Generali D, Li Y. Sobhani N, et al. Int J Mol Sci. 2020 Jun 8;21(11):4087. doi: 10.3390/ijms21114087. Int J Mol Sci. 2020. PMID: 32521648 Free PMC article. Review. - Targeted p21WAF1/CIP1 activation by RNAa inhibits hepatocellular carcinoma cells.
Kosaka M, Kang MR, Yang G, Li LC. Kosaka M, et al. Nucleic Acid Ther. 2012 Oct;22(5):335-43. doi: 10.1089/nat.2012.0354. Epub 2012 Aug 21. Nucleic Acid Ther. 2012. PMID: 22909100 Free PMC article. - GNL3L Is a Nucleo-Cytoplasmic Shuttling Protein: Role in Cell Cycle Regulation.
Thoompumkal IJ, Subba Rao MR, Kumaraswamy A, Krishnan R, Mahalingam S. Thoompumkal IJ, et al. PLoS One. 2015 Aug 14;10(8):e0135845. doi: 10.1371/journal.pone.0135845. eCollection 2015. PLoS One. 2015. PMID: 26274615 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous